Viavi Solutions EVP, CFO Ilan Daskal sells $2.04m in common stock

VIAVI CFO Ilan Daskal sold about 56,290 shares for roughly $2.04M at $36.25–$36.42 (weighted avg. $36.29), following a 224% YoY surge and while the stock trades near $36.13. Separately, VIAVI reported fiscal Q4’26 adjusted EPS of $0.34 vs $0.30 expected and revenue of $443.1M vs $432.62M, and guided Q1’27 revenue and EPS about 5% and $0.13 above consensus, though the shares still slipped after hours. Needham cut its price target from $68 to $60 (maintained Buy) citing valuation, with InvestingPro flagging the stock as overvalued vs fair value despite rising analyst earnings expectations.

Analysis

The main market signal is not the insider sale itself; it is that management chose to monetize after a multi-bagger move and into a valuation regime where the stock now trades more like a momentum compounder than a cyclical industrial. In that setup, even solid beats stop being enough: the next leg depends on repeated estimate revisions, not one-quarter execution. That makes the risk/reward asymmetric to the downside if growth merely normalizes, because the multiple can compress faster than earnings can compound.

Second-order, the read-through is broader than VIAV. If the market decides the name has already priced in the profitability inflection, similar high-beta test-and-measure or network-capex beneficiaries can de-rate on the same “good news, bad stock” pattern. Competitors with cleaner margins and more consistent free cash flow, such as KEYS, may look relatively better if customers are still cautious on carrier and optical spending; the flip side is that any disappointment in the next guide would likely hit the whole telecom-capex basket, not just VIAV.

The near-term catalyst path is 1-3 months: analyst revisions and the next commentary on demand durability. The thesis breaks if management delivers another upward guide, proves durable free-cash-flow conversion, and shows the prior quarter was the start of a sustained re-rating rather than a peak-margin blip. Contrarian view: the post-earnings selloff may already have partially de-risked the name, so this is not a blind short — it is a valuation-dependent fade, best expressed only on strength or through defined-risk structures.

Key Decisions for Investors

• Initiate a 6-10 week bearish VIAV structure on rallies: buy a put spread or short-dated put spread targeting a re-rate lower if the stock fails to hold post-earnings gains; use defined risk because borrow/vol can be unstable.
• Pair trade: long KEYS / short VIAV over 1-3 months to isolate valuation and execution quality within test-and-measure exposure; thesis is that higher-quality cash flow should outperform if the market de-risks the group.
• Do not chase VIAV on strength above the current post-earnings range; wait for either another guide-up or a pullback before establishing exposure, because the stock is already pricing in a lot of the recovery.
• Set an alert for any follow-on estimate cuts or a weaker next-quarter revenue guide; that would be the cleanest trigger to add to a short or hedge, since it would falsify the ‘profitability inflection’ narrative.
• If taking longs, prefer a basket or peer exposure over outright VIAV until free cash flow and margin durability are proven for 2 consecutive quarters.